📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-16 17:40
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Yatharth Hospital Shareholders Approve Preferential Issue and Capital Hike at EGM
Yatharth Hospital has secured shareholder approval for all five resolutions tabled at its Extraordinary General Meeting held on October 15, 2026. The key approvals include an increase in authorized share capital, issuance of securities (equity shares and warrants) via preferential issue, and granting special rights to investors and promoters. Notably, resolution 2 for the preferential issue passed with 99.26% overall votes in favour, though institutional resistance was elevated on governance terms. Resolution 5 regarding an Upside Share Arrangement witnessed 38.45% votes against, passing with 61.55% approval as promoters were ineligible to vote.
Confidence: HIGH
What changedShareholders officially approved the preferential allotment of shares/warrants and related investor rights agreements at the EGM.
Why it mattersThe approval clears regulatory requirements for onboarding a strategic financial investor and raising fresh equity capital to fund its bed capacity target expansion toward ~3,000 beds.
Preferential Issue approval rate: 99.26%Upside Share Arrangement against votes: 38.45%Total votes polled (Res 1 & 2): 70439137EGM Date: October 15, 2026
📅 Short termClearance of voting removes procedural uncertainty around the preferential fundraise, with market focus now shifting to allotment notices and pricing.
📈 Long termSecuring equity capital supports Yatharth's stated strategy to expand bed count from 1,185 toward 3,000, though substantial dissent by institutional investors on special rights warrants governance monitoring.
⚠ Risk flags
- Equity dilution from preferential shares and warrants
- High institutional investor dissent (over 40%) on special rights and upside sharing arrangements
Key Highlights
Resolution 1 to increase authorized share capital passed with 99.99% overall approval (70,429,715 votes in favour).
Resolution 2 approving preferential issue of equity shares and warrants cleared with 99.26% in favour and 0.74% against.
Resolution 3 granting special investor rights passed with 91.71% overall approval, despite 43.08% institutional votes against.
Resolution 4 granting rights to promoters passed with 89.54% favour, facing 49.45% institutional opposition.
Resolution 5 approving the Upside Share Arrangement passed with a narrower 61.55% majority (38.45% against).
👀 What to Watch
Track subsequent exchange disclosures detailing the exact issue price, total capital raised, dilution quantum, and specific deployment towards planned hospital expansions (e.g., Faridabad, Model Town, Agra).
Yatharth Concludes EGM on Preferential Issue to Advent International Affiliate
Yatharth Hospital concluded its Extra-Ordinary General Meeting on October 15, 2026, to approve a strategic preferential issue of equity shares and warrants to Rasmalai Limited, an affiliate of Advent International. The EGM saw attendance from 74 members (4 promoter group, 70 public) out of 101,829 total shareholders as of October 8, 2026. Key resolutions put to vote included increasing authorised share capital, preferential issuance, amendment of Articles of Association, special investor rights, and an upside share arrangement. Scrutinizer voting results under Regulation 44(3) are awaited to confirm formal shareholder approval.
Confidence: HIGH
What changedShareholders have voted on a strategic preferential investment by Advent International's affiliate, with final voting scrutiny underway.
Why it mattersBacking from a major global PE firm like Advent International provides growth capital and balance sheet support to fund network expansion and capacity targets towards 3,000 beds.
Members present at EGM: 74Total members on cut-off date: 101829Cut-off date: October 08, 2026Total resolutions put to vote: 5
📅 Short termScrutinizer voting outcome expected within two working days; formal approval will clear the path for allotment of equity shares and warrants.
📈 Long termStrategic backing by Advent International brings governance support, operational expertise, and capital to accelerate hospital network expansions in North India.
⚠ Risk flags
- Equity dilution from preferential shares and warrants
- Special rights granted to incoming investor could alter governance dynamics
Key Highlights
Concluded 1st/2026-27 EGM on October 15, 2026, with 74 members attending via video conferencing.
Total registered shareholders stood at 101,829 as of the cut-off date of October 08, 2026.
Shareholders voted on 5 key resolutions, including preferential issue of shares/warrants to Advent affiliate Rasmalai Limited.
Resolutions include adoption of amended Articles of Association for investor/promoter rights and an upside share arrangement.
👀 What to Watch
Track the upcoming disclosure of final voting results under Regulation 44(3) and regulatory filings detailing the exact capital raised, dilution percentage, and deployment plans.
Yatharth Hospital Issues EGM Corrigendum for ₹3,150 Cr Preferential Equity & Warrant Issue
Yatharth Hospital has issued a corrigendum to its October 15, 2026 EGM notice following clarifications requested by the NSE regarding its proposed preferential issue. The company is offering 1,30,26,516 equity shares at ₹985.17 per share to raise ₹1,283.33 Cr and up to 1,89,47,664 warrants at ₹985.17 (raising ~₹1,866.67 Cr on exercise). Out of the total proceeds, ₹2,362.50 Cr is earmarked for hospital network expansion and infrastructure development over a 3-year timeline, with the remaining allocated for general corporate purposes.
Confidence: HIGH
What changedClarifications added to the EGM notice on warrant tenure, valuation mechanism, and detailed 3-year deployment timelines for hospital network expansion.
Why it mattersThe fundraise (~₹3,150 Cr total upon full conversion) is massive relative to Yatharth's current net worth (₹1,619 Cr) and market cap (~₹9,926 Cr), providing significant capital to accelerate hospital acquisitions and capacity growth.
Equity shares issue size: ₹12,83,33,32,767.72Issue price per share/warrant: ₹985.17Subscription warrants offered: 1,89,47,664EGM Date: October 15, 2026Fundraise vs Market Cap: ~31.7%
📅 Short termShareholder approval at the EGM on October 15, 2026, and receipt of final in-principle exchange approvals will be the immediate milestones.
📈 Long termIf successfully deployed over the stated 3-year horizon, the ~₹2,362 Cr network expansion budget can significantly scale the hospital bed capacity towards its 3,000-bed target.
⚠ Risk flags
- Equity dilution of ~3.2 crore shares upon full warrant exercise
- Execution risk associated with aggressive hospital acquisitions and integration
Key Highlights
Preferential equity issue of 1,30,26,516 shares at ₹985.17 each to raise ₹1,283.33 Cr
Issuance of up to 1,89,47,664 warrants at ₹985.17 each with 25% payable upfront and 18-month tenure
₹1,312.50 Cr from share/warrant allotment plus ₹1,050 Cr from warrant conversion earmarked for hospital network expansion
Floor price benchmarked at ₹984.70 (10 trading days' VWAP) and registered valuer price of ₹900.60 per share
👀 What to Watch
Track the outcome of shareholder voting at the Extraordinary General Meeting on October 15, 2026, and subsequent receipt of final stock exchange in-principle approvals for the preferential allotment.
Yatharth Hospital Calls EGM to Raise Authorised Capital to ₹150 Cr for Preferential Issue
Yatharth Hospital has issued a notice convening an Extra-Ordinary General Meeting (EGM) on October 15, 2026. The company is seeking shareholder approval to increase its authorised share capital from ₹115 crore to ₹150 crore via the creation of 3.50 crore new equity shares. The capital expansion is intended to facilitate the issuance and allotment of subscription shares and warrants to an investor via a preferential issue on a private placement basis. In addition, the agreement establishes reserved matter thresholds including annual M&A up to ₹400 crore and capex up to ₹300 crore.
Confidence: HIGH
What changedThe board has convened an EGM to amend the Memorandum of Association and approve a preferential issue of equity shares and warrants.
Why it mattersEnables an equity infusion to fund hospital network expansions and strategic acquisitions while setting formal governance and capital expenditure limits under the investment agreement.
Current Authorised Capital: INR 115,00,00,000Proposed Authorised Capital: INR 150,00,00,000New Shares Created: 3,50,00,000 equity sharesM&A Reserved Matter Threshold: INR 400,00,00,000 per FYCapex Reserved Matter Threshold: INR 300,00,00,000 per FY
📅 Short termE-voting runs from October 12 to October 14, 2026, ahead of the October 15 EGM; investor attention will focus on equity dilution and issue pricing details.
📈 Long termProvides long-term growth capital to accelerate bed capacity additions toward the 3,000-bed target across North India, backed by institutional oversight.
⚠ Risk flags
- Equity dilution from preferential shares and warrant conversion
- Regulatory approval required from Competition Commission of India (CCI)
Key Highlights
Authorised share capital proposed to increase from ₹115 crore to ₹150 crore
Creation of 3.50 crore additional equity shares of face value ₹10 each
Preferential issuance of equity shares and subscription warrants to an institutional investor
EGM scheduled for October 15, 2026, with cut-off date on October 08, 2026
Reserved matters set governance limits on annual M&A (>₹400 crore) and capex (>₹300 crore)
👀 What to Watch
Track voting results of the EGM on October 15, 2026, and watch for subsequent filings disclosing the final issue price, total dilution, and exact identity of the incoming investor.
Yatharth Approves ₹3,150 Cr Preferential Issue to Rasmalai Ltd for 24.87% Stake
Yatharth Hospital has approved a preferential issue of equity shares and warrants to Cyprus-based Rasmalai Limited, raising up to ₹3,150 Cr at ₹985.17 per share. The issue represents 24.87% of the post-issue share capital on a fully diluted basis, comprising 1.30 crore equity shares (₹1,283.33 Cr) and 1.89 crore warrants (₹1,866.67 Cr). This massive capital infusion compares to the company's current market cap of ₹9,792 Cr (~32%) and TTM revenue of ₹1,200 Cr (~2.6x). The deal also includes an upside-sharing agreement rewarding promoter Dr. Ajay Tyagi if the investor achieves >3x return.
Confidence: HIGH
What changedBoard approved raising ₹3,150 Cr from Rasmalai Limited via shares and warrants, increasing authorised capital to ₹150 Cr and amending MoA/AoA.
Why it mattersThe fundraise injects capital equivalent to nearly double the company's net worth (₹1,619 Cr), providing massive liquidity to accelerate its 3,000-bed capacity expansion target.
Total fundraise: ₹3,150.00 CrIssue price per share/warrant: ₹985.17Diluted stake to investor: 24.87%Fundraise vs Market Cap: ~32.2%Fundraise vs TTM Revenue: ~262.5%
📅 Short termStock likely to react to the massive liquidity infusion priced close to current market levels (₹985.17 vs CMP ₹1,044.50), pending shareholder vote at the October 15, 2026 EGM.
📈 Long termTransformational balance sheet expansion enabling aggressive M&A and greenfield hospital additions across North India, though accompanied by ~25% equity dilution.
⚠ Risk flags
- Significant equity dilution of 24.87% on a fully diluted basis
- Promoter incentive arrangement tied to investor exit returns requires scrutiny by public shareholders
- Subject to shareholder and regulatory/governmental approvals
Key Highlights
Preferential issue to Rasmalai Limited aggregates up to ₹3,150.00 Cr at ₹985.17 per security
Allotment includes 1,30,26,516 equity shares (₹1,283.33 Cr) and 1,89,47,664 convertible warrants
Securities represent 24.87% post-issue diluted equity; investor classified as a public shareholder
Authorised share capital increased from ₹115 Cr to ₹150 Cr via Memorandum amendment
EGM scheduled for October 15, 2026 to seek shareholder approval
👀 What to Watch
Track shareholder approval at the EGM on October 15, 2026, and subsequent deployment plans for the ₹3,150 Cr proceeds toward hospital network expansion.
Yatharth Hospital approves ₹3,150 Cr preferential issue to Rasmalai Limited
Yatharth Hospital has approved a preferential issue of equity shares and warrants aggregating up to ₹3,150.00 Cr to Cyprus-based Rasmalai Limited at ₹985.17 per unit. The transaction represents 24.87% of post-issue share capital on a fully diluted basis, comprising ₹1,283.33 Cr in equity shares and ₹1,866.67 Cr in convertible warrants (25% upfront). The fundraise is massive, equivalent to ~32.2% of its current market cap of ₹9,792 Cr and over 2.6x its TTM revenue of ₹1,200 Cr. An EGM is scheduled on October 15, 2026, to seek shareholder approval for the capital increase and preferential allotment.
Confidence: HIGH
What changedBoard approved issuing up to 1.30 Cr shares and 1.89 Cr warrants to Rasmalai Limited for ₹3,150 Cr, giving the investor a 24.87% fully diluted stake.
Why it mattersProvides substantial growth capital nearly tripling current net worth (₹1,619 Cr) to aggressively fund bed capacity additions toward its 3,000-bed roadmap, though with significant 24.87% equity dilution.
Total fundraise value: ₹3,150,00,02,910.60Fundraise vs Market Cap: ~32.2%Issue price per share/warrant: ₹985.17Dilution (fully diluted): 24.87%Upfront warrant payment: 25% (₹246.29 per warrant)EGM Date: 15th October 2026
📅 Short termStock reaction will reflect the large capital influx at an issue price of ₹985.17 (a modest ~5.7% discount to the current market price of ₹1,044.50) alongside investor scrutiny on the substantial dilution.
📈 Long termTransformational balance sheet expansion provides massive war-chest to accelerate hospital acquisitions and greenfield/brownfield expansion toward 3,000 operational beds across North India.
⚠ Risk flags
- Substantial equity dilution of 24.87% on a fully diluted basis
- Promoter upside incentive tied to investor exit returns may draw minority investor governance scrutiny
Key Highlights
Total capital raise of up to ₹3,150,00,02,910.60 via preferential allotment of shares and warrants
Issue includes 1,30,26,516 equity shares (₹1,283.33 Cr) and 1,89,47,664 warrants at ₹985.17 each
Investor to hold a 24.87% stake on a fully diluted basis, classified as a public shareholder
Promoter incentive arrangement grants Dr. Ajay Tyagi upside shares if investor achieves >3x MOM return
Authorised share capital to be increased from ₹115 Cr to ₹150 Cr; EGM convened for October 15, 2026
👀 What to Watch
Track shareholder approval at the EGM on October 15, 2026, followed by clarity from management on the deployment plan across brownfield/greenfield bed expansions.
Advent International to Invest Rs 3,150 Cr for 24.9% Stake in Yatharth Hospitals
Global private equity firm Advent International has entered into a definitive agreement to invest Rs 3,150 crore of primary capital in Yatharth Hospitals for a 24.9% minority stake. The primary capital infusion is highly significant, representing approximately 32% of Yatharth's current market capitalization of Rs 9,792 crore and over 2.6x its TTM revenue of Rs 1,200 crore. The promoter Tyagi family will continue to remain the largest shareholder. The transaction remains subject to customary closing conditions and will support the company's expansion from ~2,800 operational beds across nine hospitals to its announced ~3,250 bed target.
Confidence: HIGH
What changedAdvent International agreed to inject Rs 3,150 crore of primary equity into Yatharth Hospitals for a 24.9% stake.
Why it mattersThe massive capital infusion substantially strengthens Yatharth's balance sheet, creating an extensive war chest for aggressive greenfield/brownfield hospital expansions and M&A in North India without incurring debt.
Investment Amount: Rs 3,150 croreStake Acquired: 24.9%Fundraise vs Market Cap: ~32.2%Current Bed Capacity: ~2,800 bedsAnnounced Bed Capacity: ~3,250 beds
📅 Short termLikely to trigger positive market sentiment due to strong institutional backing from a premier global healthcare investor and substantial capital expansion runway.
📈 Long termTransformational for Yatharth's scale, accelerating bed capacity expansion, technological upgrades (robotics/oncology), and strategic acquisitions across North India.
⚠ Risk flags
- Closing conditions and regulatory approvals pending
- Equity dilution of existing shareholders from primary issuance
- Execution and capital deployment risk for such a large cash pile
Key Highlights
Advent International to invest Rs 3,150 crore of primary capital
Advent will acquire a 24.9% minority stake upon completion
Primary infusion equals ~32% of current market cap of Rs 9,792 crore and ~1.9x current net worth of Rs 1,619 crore
Promoter family (Tyagi family) to remain the largest shareholder
Network currently comprises 9 multi-speciality hospitals with ~2,800 beds and announced capacity of ~3,250 beds
👀 What to Watch
Track the regulatory and shareholder approval timelines, customary closing milestones, and subsequent disclosures regarding preferential issue pricing, dilution details, and deployment plans for the Rs 3,150 crore infusion.
Yatharth Approves ₹3,150 Cr Preferential Issue to Rasmalai Ltd for 24.87% Stake
Yatharth Hospital's board has approved a preferential issue of equity shares and warrants aggregating up to ₹3,150.00 Cr to Cyprus-based Rasmalai Limited, representing a 24.87% post-issue fully diluted stake. The transaction comprises 1.30 Cr shares (₹1,283.33 Cr) and 1.89 Cr warrants (₹1,866.67 Cr) at an issue price of ₹985.17 per unit (against a market price of ₹1,044.50). This massive capital injection amounts to ~32% of the company's current market cap of ₹9,792 Cr and almost doubles its net worth of ₹1,619 Cr. An EGM has been scheduled for October 15, 2026, to seek shareholder approval for the transaction, capital increase, and special investor rights.
Confidence: HIGH
What changedThe board approved a ₹3,150 Cr equity and warrant placement to Rasmalai Limited for a 24.87% post-dilution stake, alongside raising authorized share capital to ₹150 Cr.
Why it mattersThe capital raised represents nearly 32% of current market cap and 1.95x net worth, giving the company massive financial muscle to accelerate its target of reaching 3,000 hospital beds.
Total fundraise value: ₹3,150,00,02,910.60Fundraise vs Market Cap: ~32.2%Issue price per share/warrant: INR 985.17Post-issue stake (fully diluted): 24.87%EGM Date: 15th October 2026
📅 Short termMarket reaction will likely focus on the sizeable capital infusion versus the 24.87% equity dilution priced close to the regulatory floor of ₹984.70.
📈 Long termProvides war chest funding to execute large-scale greenfield and brownfield hospital expansions towards its 3,000-bed target without taking on significant debt.
⚠ Risk flags
- Equity dilution of 24.87% on a fully diluted basis
- Promoter upside-sharing agreement and investor special governance rights subject to public shareholder scrutiny
- Execution risk on effectively deploying such a large pool of capital without diluting ROCE
Key Highlights
Approved preferential issue raising up to ₹3,150.00 Cr via equity and warrants to Rasmalai Limited
Issuance of 1,30,26,516 equity shares and 1,89,47,664 warrants at ₹985.17 each (floor price ₹984.70)
Investor to hold a 24.87% post-issue equity stake on a fully diluted basis as a public shareholder
Authorised share capital increased from ₹115 Cr to ₹150 Cr
EGM convened for October 15, 2026, to seek required shareholder approvals
👀 What to Watch
Track the voting outcome of the EGM on October 15, 2026, and watch for management disclosures regarding the specific deployment schedule across planned hospital expansions and bed additions.
Yatharth Receives Total Tax Demands of ₹59.74 Cr (incl. Interest) Across Group; Filing Appeals
Yatharth Hospital and its subsidiaries (AKS Medical and Ramraja Multispeciality) have received final assessment orders concluding past income tax proceedings. Aggregate demands stand at Rs 29.66 Cr tax plus Rs 11.42 Cr interest for Yatharth, Rs 8.50 Cr tax plus Rs 2.48 Cr interest for AKS, and Rs 5.64 Cr tax plus Rs 2.04 Cr interest for Ramraja, totaling Rs 59.74 Cr. This total demand represents ~35% of FY26 TTM PAT (Rs 171 Cr). The company is appealing before the CIT (Appeals), expects substantial relief, and has made no financial provisions.
Confidence: HIGH
What changedIncome tax assessment proceedings across opened assessment years have formally concluded with final demand orders issued against the parent and two subsidiaries.
Why it mattersThe cumulative demand of Rs 59.74 Cr is substantial relative to annual profitability (~35% of TTM PAT), though the company has not provided for it pending appellate resolution.
Yatharth Parent Tax Demand: Rs. 29.66 CroresYatharth Parent Interest Demand: Rs. 11.42 CroresAKS Tax & Interest Demand: Rs. 10.98 CroresRamraja Tax & Interest Demand: Rs. 7.68 CroresTotal Demand vs TTM PAT: ~34.9%
📅 Short termLitigation risk may create near-term overhang; key focus will be whether tax authorities demand a mandatory pre-deposit (typically up to 20%) during the appeal process.
📈 Long termIf demands are upheld, it would impact net cash reserves and require provisions against P&L, though core hospital operations and bed expansions remain unaffected.
⚠ Risk flags
- Tax liability crystallisation risk if CIT (Appeals) dismisses petitions
- Potential cash outflow if a pre-deposit is mandated to stay recovery proceedings
- No financial provision created in current accounts
Key Highlights
Final assessment orders conclude proceedings from AY 2014-15 to AY 2024-25 for Yatharth, resulting in Rs 29.66 Crores tax plus Rs 11.42 Crores interest.
Subsidiary AKS Medical assessed demand of Rs 8.50 Crores plus interest of Rs 2.48 Crores for AY 2022-23 to AY 2024-25.
Subsidiary Ramraja assessed demand of Rs 5.64 Crores plus interest of Rs 2.04 Crores for AY 2023-24.
Total combined demand across the group stands at Rs 59.74 Crores (tax of Rs 43.80 Crores plus interest of Rs 15.94 Crores).
Company is filing appeals before CIT (Appeals) and has opted not to create any financial provision.
👀 What to Watch
Track the admission and hearing outcomes of the appeals filed before the CIT (Appeals), and check whether any stay on demand requires partial pre-deposits.
Q1 Revenue up 51% YoY to ₹392.7 Cr; EBITDA up 39% to ₹91.7 Cr with ARPOB at ₹34,758
Yatharth reported a 51% YoY revenue growth in Q1 to ₹392.7 Cr (INR 3,927 million) and a 39% YoY increase in EBITDA to ₹91.7 Cr, driven by mature units and rapid scaling of new hospitals. Newer hospitals contributed 27% to total revenue, with Faridabad Sector 20 achieving EBITDA breakeven within 9 months and Agra delivering 20%+ EBITDA margins. Group ARPOB rose 7% YoY to an all-time high of ₹34,758, with premium NCR facilities crossing the ₹50,000 mark. The company currently operates 2,555 beds and reiterated its roadmap to reach 5,000 beds over the next few years, alongside declaring a maiden 5% interim dividend.
Confidence: HIGH
What changedYatharth published its Q1FY27 earnings call transcript highlighting record quarterly revenue, rapid acquisition turnaround, and plans for network expansion.
Why it mattersDemonstrates successful integration of acquired hospital assets, high ARPOB expansion via advanced specialties (oncology, robotics), and consistent operating leverage.
Q1 Revenue: INR 3,927 millionQ1 EBITDA: INR 917 millionQ1 PAT: INR 454 millionGroup ARPOB: INR 34,758Current Bed Capacity: 2,555 beds
📅 Short termRobust execution and improving profitability across acquired hospitals provide strong fundamental support.
📈 Long termDoubling bed capacity to 5,000 beds and scaling high-margin oncology and robotics offerings provide strong multi-year compounding potential.
⚠ Risk flags
- Geographic concentration in Delhi-NCR and North India
- Execution and clinical talent retention risks associated with rapid bed additions
Key Highlights
Q1 revenue increased 51% YoY to INR 3,927 million; consolidated EBITDA reached INR 917 million (23.3% margin, adjusted 28.1%).
Consolidated PAT reached INR 454 million with cash profit growing 32% YoY.
Blended ARPOB hit an all-time high of INR 34,758, led by Noida Extension and New Delhi exceeding INR 50,000.
Newer hospitals contributed INR 1,067 million (27% of revenue mix) as turnaround playbook delivered fast breakevens.
Operational bed network expanded to 2,555 beds, targeting over 3,200 beds near term and 5,000 beds within 3 years.
👀 What to Watch
Track the commercial launch timeline of the 250-bed Gurugram hospital scheduled for Q1 of the next fiscal, as well as occupancy gains in Noida Extension and brownfield expansions.
51% YoY Revenue Growth in Q1 FY27; Faridabad Unit Achieves EBITDA Breakeven
Yatharth Hospital reported a robust Q1 FY27 with revenue growing 51% YoY to ₹392.7 cr, significantly higher than the previous year's quarterly average. Operational efficiency improved as occupancy reached 68% (up from 65% YoY) and ARPOB increased 7% YoY to ₹34,758. Notably, the Faridabad Sector-20 unit achieved EBITDA breakeven within just 9 months, while the Agra unit delivered >20% margins in its first full quarter. The company also declared its first interim dividend of 5% of face value.
Confidence: HIGH
What changedThe company has successfully integrated recent acquisitions, with new units like Agra and Faridabad reaching profitability milestones faster than industry averages.
Why it mattersThe rapid turnaround of new units validates the company's acquisition playbook and supports its high P/E valuation (49.2) by demonstrating scalable growth in the Delhi-NCR region.
Q1 FY27 Revenue: ₹392.7 crRevenue vs TTM Revenue: 32.7%ARPOB: ₹34,758Adjusted EBITDA Margin: 28.1%Occupancy Rate: 68%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the strong top-line growth and the achievement of EBITDA breakeven in the Faridabad unit.
📈 Long termThe expansion to 2,800+ beds and entry into high-ARPOB segments like robotics and oncology provide a structural growth runway for the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geographic concentration in North India
- High attrition risk of specialized medical professionals
- Ramp-up risks for the upcoming Gurugram facility
Key Highlights
Revenue increased 51% YoY to ₹392.7 cr, representing ~33% of the total TTM revenue in a single quarter.
Adjusted EBITDA margin (excluding ramp-up losses) stood at 28.1%, compared to the consolidated 23.3%.
Bed occupancy improved to 68% from 65% in Q1 FY26, despite a significant increase in operational beds.
New hospitals (Faridabad, Delhi, Agra) now contribute 27% to the total revenue mix.
Total bed capacity reached 2,800+, including the 250-bed Gurugram facility expected by Q1 FY2028.
👀 What to Watch
Watch for the operational commencement of the Gurugram facility in Q1 FY2028 and the ability to maintain the 28% adjusted EBITDA margin as newer units mature.
₹0.50 Dividend Declared and 2.5 Lakh Share ESOP Scheme Approved by Yatharth Hospital
Yatharth Hospital reported a 34.9% YoY increase in standalone revenue for Q1 FY27, reaching ₹176.3 Cr compared to ₹130.7 Cr in the previous year. The Board declared a first interim dividend of ₹0.50 per share (5% of face value), with a total payout of ₹4.82 Cr. Additionally, a new ESOP Scheme 2026 was approved, covering 250,000 equity shares to incentivize and retain key employees. While revenue growth was robust, standalone PAT grew more modestly at 3.9% YoY to ₹28.17 Cr.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial performance, initiated its first dividend for the fiscal year, and introduced a new employee stock option framework.
Why it mattersThe strong revenue growth validates the company's expansion strategy in North India, while the ESOP scheme is a critical tool for retaining specialized medical professionals in a high-attrition industry.
Q1 Standalone Revenue: ₹176.3 CrYoY Revenue Growth: 34.9%Interim Dividend: ₹0.50 per shareDividend Payout vs TTM PAT: ~2.8%ESOP Shares: 2,50,000 unitsStandalone PAT: ₹28.17 Cr
📅 Short termThe stock may see positive sentiment due to the dividend declaration and strong top-line growth, with immediate focus on the August 14 record date.
📈 Long termThe ESOP scheme supports long-term talent retention, which is vital for the company's goal of reaching 3,000 beds and increasing ARPOB through specialized treatments.
⚠ Risk flags
- PAT growth (3.9%) significantly lagging revenue growth (34.9%) suggesting margin pressure
- Potential equity dilution from the new ESOP scheme
Key Highlights
Standalone revenue from operations grew 34.9% YoY to ₹176.3 Cr in Q1 FY27.
Interim dividend of ₹0.50 per share declared with a record date of August 14, 2026.
Approved ESOP 2026 scheme involving 250,000 equity shares, representing approximately 0.26% of total equity.
Standalone Profit After Tax (PAT) for the quarter stood at ₹28.17 Cr vs ₹27.12 Cr YoY.
Total dividend payout for this interim period amounts to ₹4.82 Cr.
👀 What to Watch
Investors should monitor the company's ability to translate high revenue growth into better bottom-line margins, as PAT growth lagged revenue this quarter. Watch for the upcoming record date of August 14, 2026, for dividend eligibility.
Rs 0.50 Interim Dividend: Yatharth Hospital Sets August 14, 2026, as Record Date
Yatharth Hospital has declared its first interim dividend for FY 2026-27 at Rs 0.50 per equity share (5% of face value). The Board of Directors fixed August 14, 2026, as the record date to determine shareholder eligibility. The total paid-up share capital involved is Rs 96.35 crore. Based on the current stock price of Rs 865.7, this specific payout represents a nominal yield of approximately 0.06%.
Confidence: HIGH
What changedThe company has officially scheduled the record date and confirmed the quantum for its first interim dividend of the 2026-27 financial year.
Why it mattersWhile the dividend amount is small relative to the share price, it signals a commitment to shareholder returns alongside the company's aggressive 30% growth strategy and geographic expansion.
Dividend per share: Rs 0.50Dividend as % of Face Value: 5%Record Date: August 14, 2026TTM EPS: Rs 18.28Dividend Yield (approx): 0.06%
📅 Short termThe stock may see a minor price adjustment on the ex-dividend date (typically one business day before the record date) reflecting the Rs 0.50 payout.
📈 Long termLimited structural significance; the company's long-term value is tied to its ability to scale ARPOB (currently Rs 25,080) and integrate new acquisitions in North India.
Key Highlights
Interim dividend declared at Rs 0.50 per equity share of face value Rs 10 each.
Record date for determining entitlement is fixed for Friday, August 14, 2026.
Dividend payment will be processed within 30 days from the declaration date (August 10, 2026).
Total paid-up share capital of the company stands at Rs 96,35,43,570.00.
The dividend is subject to Tax Deduction at Source (TDS) as per the Income Tax Act, 1961.
👀 What to Watch
Investors should note the record date of August 14 to ensure they hold shares in their demat accounts by this date to receive the payout. The focus should remain on the company's execution of its 3,000-bed capacity target rather than this minor dividend yield.
₹0.50 Interim Dividend and 34.8% YoY Revenue Growth for Yatharth Hospital in Q1 FY27
Yatharth Hospital has declared its first interim dividend of ₹0.50 per share (5% of face value) for FY27, amounting to a total payout of ₹4.82 Cr. The company reported standalone revenue of ₹176.31 Cr for Q1 FY27, representing a 34.8% growth compared to ₹130.72 Cr in the same quarter last year. Additionally, the board approved a new ESOP scheme for 250,000 shares to incentivize employees. The record date for the dividend is fixed for August 14, 2026.
Confidence: HIGH
What changedThe company has initiated its dividend cycle for FY27 and reported strong double-digit revenue growth for the first quarter.
Why it mattersThe dividend payout, though small relative to PAT (~2.8%), signals management's confidence in cash flows, while the revenue growth validates the company's expansion strategy in the North India market.
Interim Dividend: ₹0.50 per shareTotal Dividend Payout: ₹4.82 CrDividend vs TTM PAT: ~2.8%Q1 Standalone Revenue Growth (YoY): 34.8%ESOP Shares: 2,50,000 unitsRecord Date: August 14, 2026
📅 Short termThe stock may see mild positive sentiment leading up to the record date of August 14, supported by the revenue growth figures.
📈 Long termThe company's ability to maintain high growth rates while expanding its bed capacity toward the 3,000-bed target remains the primary long-term value driver.
⚠ Risk flags
- Geographic concentration in North India
- Potential equity dilution from the new ESOP scheme
Key Highlights
Declared first interim dividend of ₹0.50 per equity share for FY27
Total dividend payout quantified at ₹4,81,77,178.50
Standalone revenue from operations increased 34.8% YoY to ₹176.31 Cr
Record date for dividend entitlement set for August 14, 2026
Approved ESOP 2026 scheme covering 250,000 equity shares
👀 What to Watch
Investors should monitor the sustainability of the 34% revenue growth and the impact of the new ESOP scheme on future earnings per share (EPS) dilution.
51% YoY Revenue Growth in Q1 FY27; Faridabad Unit Hits EBITDA Breakeven
Yatharth Hospital reported a robust Q1 FY27 with revenue surging 51% YoY to Rs 392.7 Cr, significantly outpacing its historical growth rates. While consolidated EBITDA margins were 23.3%, the adjusted margin (excluding ramp-up losses from new units) reached a strong 28.1%. Operational efficiency improved with occupancy rising to 68% and ARPOB increasing 7% YoY to Rs 34,758. Notably, the Faridabad Sector-20 unit achieved EBITDA breakeven within just 9 months of operation, and the company declared its first interim dividend of 5% of face value.
Confidence: HIGH
What changedThe company has demonstrated a successful 'acquisition playbook' with the Agra unit turning profitable (>20% margin) in its first full quarter and Faridabad hitting breakeven ahead of typical industry timelines.
Why it mattersThe strong performance validates Yatharth's strategy of aggressive inorganic expansion in North India and its ability to drive higher-value clinical work (oncology/robotics), which is reflected in the rising ARPOB.
Q1 Revenue: Rs 392.7 CrRevenue vs TTM Revenue: 32.7%Adjusted EBITDA Margin: 28.1%ARPOB: Rs 34,758Occupancy Rate: 68%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the strong top-line growth and the rapid turnaround of newly acquired units, which reduces concerns over near-term margin dilution.
📈 Long termThe company is structurally positioned for growth with a clear path to 3,000 beds and a proven ability to integrate acquisitions, though geographic concentration in Delhi-NCR remains a factor to watch.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Ramp-up risks for newer hospitals
- Geographic concentration in North India
- High dependency on specialized medical professionals
Key Highlights
Revenue grew 51% YoY to Rs 392.7 Cr, representing approximately 33% of the total TTM revenue in a single quarter
Adjusted EBITDA margin stood at 28.1% after excluding ramp-up losses from Model Town and Faridabad units
Faridabad Sector-20 unit achieved EBITDA breakeven in a record 9 months
ARPOB increased to Rs 34,758, a 7% growth compared to Q1 FY26
Total bed capacity reached 2,800+ including the 250-bed Gurugram facility expected by Q1 FY2028
👀 What to Watch
Investors should monitor the margin trajectory as the Model Town and Faridabad units scale up, potentially closing the gap between consolidated (23.3%) and adjusted (28.1%) margins. Track the execution timeline of the 250-bed Gurugram hospital project slated for 2028.
51% YoY Revenue Growth in Q1FY27; Yatharth Declares Maiden Interim Dividend
Yatharth Hospital reported a strong Q1FY27 with revenue surging 51% YoY to 392.7 cr, significantly outpacing its TTM growth trends. EBITDA grew 39% YoY to 91.7 cr, though margins compressed to 23.3% from 25.4% due to the ramp-up of new acquisitions. A key highlight is the Faridabad Sector-20 unit achieving EBITDA breakeven in just 9 months, while the board declared its first-ever interim dividend at 5% of face value. PAT growth was relatively muted at 8% YoY ( 45.4 cr) due to increased depreciation from recent capacity additions.
Confidence: HIGH
What changedYatharth has successfully integrated recent acquisitions, with new units now contributing over a quarter of total revenue and one achieving breakeven ahead of schedule.
Why it mattersThe results validate the company's acquisition-led growth strategy and its ability to quickly turn around new assets, supporting its long-term target of reaching ~3,250 beds.
Q1FY27 Revenue: 392.7 crRevenue vs TTM Revenue: 32.7%EBITDA Margin: 23.3%Adjusted EBITDA Margin: 28.1%New Hospital Revenue Share: 27%Interim Dividend: 5% of Face Value
📅 Short termThe stock is likely to react positively to the record revenue growth and the surprise maiden dividend, reflecting management's confidence in cash flows.
📈 Long termThe company is successfully scaling its hub-and-spoke model in North India; sustained ARPOB growth and bed additions provide a clear path for multi-year compounding.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin dilution during the initial ramp-up phase of new hospitals
- High depreciation from aggressive capacity expansion impacting net profit growth
Key Highlights
Revenue reached a record 392.7 cr in Q1FY27, up 51% YoY and 15% QoQ.
New hospitals contributed 106.7 cr, representing 27% of total group revenue.
Group ARPOB increased 7% YoY to 34,758, with premium NCR hospitals reaching the 50,000 mark.
Faridabad Sector-20 unit achieved EBITDA breakeven within a record 9 months of operations.
Adjusted EBITDA margin (excluding new unit ramp-up impacts) stood strong at 28.1%.
👀 What to Watch
Monitor the occupancy levels and margin improvement in the Agra and Faridabad units as they mature, and track the progress of the upcoming Gurugram hospital expansion.
Yatharth Q1 Standalone Revenue Up 35% YoY to ₹176 Cr; ₹0.50 Interim Dividend Declared
Yatharth Hospital reported a strong 34.9% YoY growth in standalone revenue from operations, reaching ₹176.31 Cr for Q1 FY27. However, standalone net profit grew only 3.9% YoY to ₹28.17 Cr, primarily due to a sharp rise in finance costs to ₹5.31 Cr (vs ₹0.16 Cr YoY) and doubled depreciation expenses. The board declared an interim dividend of ₹0.50 per share (5% of face value) with a record date of August 14, 2026. Additionally, a new ESOP scheme for 250,000 shares was approved to incentivize employees.
Confidence: HIGH
What changedThe company has reported its first-quarter results for FY27, initiated an interim dividend, and established a new employee stock option pool.
Why it mattersThe strong top-line growth confirms the company's successful scale-up in the North India market, though the lag in profit growth highlights the cost of aggressive expansion (higher interest and depreciation).
Q1 Standalone Revenue: ₹176.31 CrYoY Revenue Growth: 34.9%Interim Dividend: ₹0.50 per shareFinance Costs (Q1 FY27): ₹5.31 CrESOP Pool Size: 2,50,000 sharesDividend Record Date: August 14, 2026
📅 Short termThe stock may see positive sentiment from the robust revenue growth and dividend declaration, though the surge in finance costs might temper gains.
📈 Long termThe company is executing its strategy to reach 3,000 beds; long-term value depends on improving occupancy and ARPOB at new units to offset expansion costs.
⚠ Risk flags
- Sharp increase in finance costs (up >30x YoY)
- Muted PAT growth relative to revenue
- Potential equity dilution from ESOPs
Key Highlights
Standalone Revenue from operations increased 34.9% YoY to ₹176.31 Cr from ₹130.72 Cr.
Interim dividend of ₹0.50 per share declared, involving a total payout of ₹4.82 Cr.
Finance costs surged significantly to ₹5.31 Cr in Q1 FY27 compared to ₹0.16 Cr in Q1 FY26.
Depreciation and amortisation expenses rose to ₹10.09 Cr from ₹4.69 Cr YoY.
Approved 'ESOP 2026' scheme covering 250,000 equity shares, subject to shareholder approval.
👀 What to Watch
Investors should monitor the consolidated results to assess the performance of recently acquired units in Faridabad and Agra, and track if the high finance costs are transitory due to expansion debt.
Yatharth Hospital Completes ₹100 Crore Acquisition of Gurugram Hospital Asset
Yatharth Hospital has successfully finalized the acquisition of a hospital asset located in Sector 40, Gurugram, from RNY Healthcare Services Private Limited. The total consideration of ₹100 Crores has been fully paid, and the transaction formalities were completed on June 12, 2026. The asset is now registered under AKS Medical & Research Centre Private Limited, which is a wholly-owned subsidiary of the company. This acquisition marks a significant step in the company's expansion strategy within the National Capital Region (NCR).
Key Highlights
Completed acquisition of hospital asset in Sector 40, Gurugram for ₹100 Crores.
Asset registered under wholly-owned subsidiary AKS Medical & Research Centre Private Limited.
Full payment of the ₹100 Crore consideration has been executed.
Transaction follows the initial acquisition announcement made on May 13, 2026.
👀 What to Watch
Investors should monitor the integration of this new asset and its impact on bed capacity and revenue growth in the upcoming quarters. This expansion into the Gurugram market is a positive indicator of the company's scaling capabilities.
Yatharth Hospital Q4 FY26 Revenue Jumps 47% YoY to INR 3,416 Mn; FY26 PAT Up 30%
Yatharth Hospital reported a robust 36% YoY revenue growth for FY26, reaching INR 12,072 million, driven by strong performance in existing units and rapid ramp-up of new facilities. The company's EBITDA for the full year rose 30% to INR 2,921 million, while Q4 occupancy reached 71%. Strategic expansions include a new Gurugram facility and the integration of the Agra hospital, which is already generating INR 7 crore in monthly revenue. With a net cash position of INR 1,160 million, the company is well-positioned to reach its target of 5,000 beds within the next three years.
Key Highlights
Consolidated FY26 revenue grew 36% YoY to INR 12,072 million with EBITDA margins at 24.2%.
Q4 FY26 ARPOB improved to INR 33,282, with Noida Extension hitting a record INR 47.8k.
New Delhi and Faridabad Sector 20 hospitals contributed 11% to Q4 revenue with superior payer mix.
Acquired a Gurugram hospital project for INR 100 crore, expected to be operational by April 2027.
Total bed capacity reached 3,200+ with a long-term target of 5,000 beds.
👀 What to Watch
Investors should view the strong ramp-up in new hospitals and the entry into the high-ARPOB Gurugram market as key growth catalysts. The company's ability to maintain a 98% cash conversion ratio provides significant financial flexibility for further brownfield expansions.
Yatharth Hospital Q4 FY26 Revenue Surges 47% YoY to ₹3,416 Mn; EBITDA Up 37%
Yatharth Hospital delivered a robust Q4 FY26 performance with revenue growing 47% YoY to ₹3,416 million, supported by strong traction in newer hospitals which now contribute 22% of total revenue. While reported EBITDA margins dipped to 23.4% due to ramp-up costs, the adjusted EBITDA margin remained high at 30.4%. The company continues its expansion momentum with a new 250-bed Gurugram facility set to open in early FY27. Operational efficiency improved as debtor days reduced to 112 and cash conversion reached 98%.
Key Highlights
Q4 FY26 Revenue grew 47% YoY to ₹3,416 Mn, while full-year FY26 revenue rose 36% to ₹12,072 Mn.
Adjusted EBITDA margin (excluding ramp-up losses) stood at 30.4%, with reported EBITDA up 37% YoY to ₹799 Mn.
Group ARPOB increased 5% YoY to ₹33,283, led by Noida Extension at ₹47.8k and Greater Noida at ₹40.3k.
Newer hospitals in Delhi, Faridabad, and Agra contributed ₹753 Mn, representing 22% of the Group's quarterly revenue.
Strong balance sheet management with a 98% cash conversion ratio and debtor days improving from 125 to 112.
👀 What to Watch
Investors should view the strong revenue growth and successful integration of new assets as a positive sign for long-term scalability. Monitor the upcoming Gurugram facility launch and the stabilization of margins as newer hospitals reach maturity.
